Switch to:
Also traded in: Austria, Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.82
CELG's Cash-to-Debt is ranked lower than
84% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. CELG: 0.82 )
Ranked among companies with meaningful Cash-to-Debt only.
CELG' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 5.55 Max: No Debt
Current: 0.82
0.03
No Debt
Equity-to-Asset 0.31
CELG's Equity-to-Asset is ranked lower than
84% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CELG: 0.31 )
Ranked among companies with meaningful Equity-to-Asset only.
CELG' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.68  Med: 0.76 Max: 0.98
Current: 0.31
-0.68
0.98
Debt-to-Equity 1.45
CELG's Debt-to-Equity is ranked lower than
90% of the 487 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. CELG: 1.45 )
Ranked among companies with meaningful Debt-to-Equity only.
CELG' s Debt-to-Equity Range Over the Past 10 Years
Min: -4.28  Med: 0.48 Max: 2.88
Current: 1.45
-4.28
2.88
Debt-to-EBITDA 3.07
CELG's Debt-to-EBITDA is ranked lower than
68% of the 209 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. CELG: 3.07 )
Ranked among companies with meaningful Debt-to-EBITDA only.
CELG' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.35  Med: 1.87 Max: 5.18
Current: 3.07
0.35
5.18
Interest Coverage 8.74
CELG's Interest Coverage is ranked lower than
87% of the 496 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CELG: 8.74 )
Ranked among companies with meaningful Interest Coverage only.
CELG' s Interest Coverage Range Over the Past 10 Years
Min: 6.33  Med: 27.63 Max: 428.04
Current: 8.74
6.33
428.04
Piotroski F-Score: 8
Altman Z-Score: 4.03
Beneish M-Score: -2.51
WACC vs ROIC
8.83%
32.24%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 35.48
CELG's Operating Margin % is ranked higher than
93% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. CELG: 35.48 )
Ranked among companies with meaningful Operating Margin % only.
CELG' s Operating Margin % Range Over the Past 10 Years
Min: -64.94  Med: 29 Max: 35.48
Current: 35.48
-64.94
35.48
Net Margin % 27.36
CELG's Net Margin % is ranked higher than
89% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. CELG: 27.36 )
Ranked among companies with meaningful Net Margin % only.
CELG' s Net Margin % Range Over the Past 10 Years
Min: -68.02  Med: 23.31 Max: 28.88
Current: 27.36
-68.02
28.88
ROE % 44.77
CELG's ROE % is ranked higher than
97% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. CELG: 44.77 )
Ranked among companies with meaningful ROE % only.
CELG' s ROE % Range Over the Past 10 Years
Min: -48.42  Med: 24.32 Max: 44.77
Current: 44.77
-48.42
44.77
ROA % 11.73
CELG's ROA % is ranked higher than
90% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. CELG: 11.73 )
Ranked among companies with meaningful ROA % only.
CELG' s ROA % Range Over the Past 10 Years
Min: -38.07  Med: 11.43 Max: 15.8
Current: 11.73
-38.07
15.8
ROC (Joel Greenblatt) % 295.52
CELG's ROC (Joel Greenblatt) % is ranked higher than
97% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. CELG: 295.52 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CELG' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -421.4  Med: 179.18 Max: 295.52
Current: 295.52
-421.4
295.52
3-Year Revenue Growth Rate 22.80
CELG's 3-Year Revenue Growth Rate is ranked higher than
76% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. CELG: 22.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CELG' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -42.8  Med: 31 Max: 241.3
Current: 22.8
-42.8
241.3
3-Year EBITDA Growth Rate 19.30
CELG's 3-Year EBITDA Growth Rate is ranked higher than
70% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. CELG: 19.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CELG' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -34  Med: 19.35 Max: 295.8
Current: 19.3
-34
295.8
3-Year EPS without NRI Growth Rate 14.00
CELG's 3-Year EPS without NRI Growth Rate is ranked higher than
68% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. CELG: 14.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CELG' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -60.8  Med: 14.7 Max: 109.7
Current: 14
-60.8
109.7
GuruFocus has detected 2 Warning Signs with Celgene Corp CELG.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CELG's 30-Y Financials

Financials (Next Earnings Date: 2018-01-26)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2017

CELG Guru Trades in Q1 2017

Jeremy Grantham 1,900 sh (New)
Stanley Druckenmiller 82,400 sh (New)
Ray Dalio 43,412 sh (New)
John Burbank 20,710 sh (New)
David Rolfe 192,000 sh (New)
Signature Select Canadian Fund 51,450 sh (+48.27%)
Joel Greenblatt 158,126 sh (+31.79%)
Pioneer Investments 5,231,139 sh (+15.72%)
Mario Gabelli 12,709 sh (+12.08%)
Ronald Muhlenkamp 3,000 sh (unchged)
Murray Stahl 8,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 444,921 sh (unchged)
George Soros Sold Out
Ronald Muhlenkamp 72,493 sh (-0.27%)
Ken Fisher 201,869 sh (-0.80%)
Julian Robertson 286,340 sh (-4.15%)
Paul Tudor Jones 1,900 sh (-9.52%)
Steven Cohen 330,000 sh (-48.99%)
Jim Simons 132,138 sh (-82.41%)
» More
Q2 2017

CELG Guru Trades in Q2 2017

Caxton Associates 3,600 sh (New)
Lee Ainslie 19,150 sh (New)
Jim Simons 1,170,638 sh (+785.92%)
David Rolfe 799,402 sh (+316.36%)
Jeremy Grantham 3,000 sh (+57.89%)
Ken Fisher 263,929 sh (+30.74%)
Joel Greenblatt 168,817 sh (+6.76%)
Murray Stahl 8,155 sh (+1.94%)
Ronald Muhlenkamp 3,000 sh (unchged)
Steven Cohen 200,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 444,921 sh (unchged)
John Burbank Sold Out
Paul Tudor Jones Sold Out
Stanley Druckenmiller Sold Out
Steven Cohen Sold Out
Ronald Muhlenkamp 72,418 sh (-0.10%)
Pioneer Investments 5,193,810 sh (-0.71%)
Julian Robertson 283,240 sh (-1.08%)
Ray Dalio 40,801 sh (-6.01%)
Mario Gabelli 10,529 sh (-17.15%)
» More
Q3 2017

CELG Guru Trades in Q3 2017

Frank Sands 4,130 sh (New)
Stanley Druckenmiller 188,100 sh (New)
Steven Cohen 77,242 sh (New)
Ray Dalio 85,286 sh (+109.03%)
Joel Greenblatt 195,353 sh (+15.72%)
Signature Select Canadian Fund 51,850 sh (+0.78%)
Ken Fisher 265,695 sh (+0.67%)
Ronald Muhlenkamp 3,000 sh (unchged)
Lee Ainslie Sold Out
Caxton Associates Sold Out
Ronald Muhlenkamp 71,455 sh (-1.33%)
Mario Gabelli 10,250 sh (-2.65%)
Murray Stahl 7,939 sh (-2.65%)
Jeremy Grantham 2,700 sh (-10.00%)
David Rolfe 676,776 sh (-15.34%)
Julian Robertson 219,540 sh (-22.49%)
Pioneer Investments 2,522,142 sh (-51.44%)
Jim Simons 410,238 sh (-64.96%)
Eaton Vance Worldwide Health Sciences Fund 409,520 sh (-7.96%)
» More
2017

CELG Guru Trades in 2017

Spiros Segalas 3,207,054 sh (-33.95%)
» More
» Details

Insider Trades

Latest Guru Trades with CELG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2017-09-30 Add 0.67%$127.43 - $144.94 $ 106.15-22%265,695
Julian Robertson 2017-09-30 Reduce -22.49%1.63%$127.43 - $144.94 $ 106.15-22%219,540
Joel Greenblatt 2017-09-30 Add 15.72%0.06%$127.43 - $144.94 $ 106.15-22%195,353
Ronald Muhlenkamp 2017-09-30 Reduce -1.33%0.04%$127.43 - $144.94 $ 106.15-22%71,455
Mario Gabelli 2017-09-30 Reduce -2.65%$127.43 - $144.94 $ 106.15-22%10,250
Julian Robertson 2017-06-30 Reduce -1.08%0.07%$114.41 - $134.31 $ 106.15-13%283,240
Ken Fisher 2017-06-30 Add 30.74%0.01%$114.41 - $134.31 $ 106.15-13%263,929
Joel Greenblatt 2017-06-30 Add 6.76%0.02%$114.41 - $134.31 $ 106.15-13%168,817
Ronald Muhlenkamp 2017-06-30 Reduce -0.10%$114.41 - $134.31 $ 106.15-13%72,418
Mario Gabelli 2017-06-30 Reduce -17.15%$114.41 - $134.31 $ 106.15-13%10,529
Julian Robertson 2017-03-31 Reduce -4.15%0.26%$111.53 - $126.88 $ 106.15-11%286,340
Ken Fisher 2017-03-31 Reduce -0.80%$111.53 - $126.88 $ 106.15-11%201,869
Joel Greenblatt 2017-03-31 Add 31.79%0.06%$111.53 - $126.88 $ 106.15-11%158,126
Ronald Muhlenkamp 2017-03-31 Reduce -0.27%0.01%$111.53 - $126.88 $ 106.15-11%72,493
Mario Gabelli 2017-03-31 Add 12.08%$111.53 - $126.88 $ 106.15-11%12,709
George Soros 2017-03-31 Sold Out 0.01%$111.53 - $126.88 $ 106.15-11%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:GILD, NAS:BIIB, ASX:CSL, LSE:SHP, NAS:REGN, NAS:AMGN, NAS:VRTX, OCSE:NOVO B, NAS:ALXN, XKRX:068270, XKRX:207940, NAS:INCY, XMCE:GRF.P, OCSE:NZYM B, NAS:BMRN, SZSE:002252, XBRU:UCB, HKSE:01177, NAS:ALNY, OCSE:GEN » details
Traded in other countries:CELG.Austria, CLGN34.Brazil, CG3.Germany, CELG.Mexico, CELG.Switzerland, 0QYA.UK,
Headquarter Location:USA
Celgene Corp is a biotech company that discovers, develops, and commercializes therapies designed to treat cancer and immune-inflammatory related diseases. Its registered brands are Abraxane, Istodax, Otezla, Pomalyst, Revlimid, Thalomid, Vidaza.

Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U.S. in 2014.

Guru Investment Theses on Celgene Corp

David Rolfe Comments on Celgene - Jan 12, 2018

Celgene (NASDAQ:CELG)



Celgene was a top detractor to performance due to a couple negative news events released during the quarter. The company announced they would discontinue a phase III trial for their drug GED-0301 in Crohn's disease (CD) and an extension trial, following a recommendation of the Data Monitoring Committee. They also decided that another phase 1 trial for Crohn's disease would not be initiated. While a phase II trial with GED-0301 in ulcerative colitis is still ongoing, the Company is currently awaiting review of data to determine their next steps for this indication. In the absence of any information on whether the trial failure was due to something specific to CD or the drug itself, it is currently assumed to be a high-risk program for that indication. This study was deemed a high risk/low-probability study, especially when compared to other IBD drugs. However, its success could have been a blockbuster Inflammation & Immunology (I&I) asset for the company, making its failure a disappointing loss.



In addition to these trial failures, during the third quarter earnings release, management brought down 2020 guidance, partially due to the discontinuation of GED-0301 program in CD. While sales were only modest in their 2020 model, management did forecast multibillion dollar peak sales potential for the drug. The largest impact to 2020 guidance, however, was weak performance of their existing drug Otezla, which experienced headwinds due to slowing growth and increased competition in the psoriatic arthritis and psoriasis markets. The updated guidance takes into account GED-0301, the market dynamics impacting Otezla, as well as reassesses the opportunities and risks associated with the remaining phase III studies expected to read out by the end of 2018. We believe management took a conservative stance with their update and yet the resulting guide maintains more than +14% revenue growth and nearly +20% earnings growth on a compounded annual basis through 2020.



We realize there will be phase III failures; and with each failure comes the potential for more risk and less growth. We reiterate that the Company has a very broad pipeline, with 12 phase 1 studies set to read out between now and the end of this year, making setbacks like these more manageable in the longer term. Celgene has substantially more phase III assets than any other biotech company. Several of these pipeline assets are not incorporated in the current 2020 guidance, as they read out at a date when any sales potential will contribute at future dates. With nearly +20% compounded annual earnings growth through 2020 and free cash flow generation of $100 billion over the next ten years, Celgene continues to offer a compelling growth opportunity.

From David Rolfe (Trades, Portfolio)'s fourth quarter 2017 shareholder commentary.

Check out David Rolfe latest stock trades

Spiros Segalas Commentary on Celgene - Jul 10, 2017

Celgene (NASDAQ:CELG) rose on positive results from a trial of an experimental compound to treat relapsed/refractory multiple myeloma. We consider Celgene, with its robust revenue and earnings, and deep pipeline, one of the biotechnology sector’s most fundamentally sound companies. As of the end of the period, the Fund focused its holdings in high-conviction biotechnology and specialty pharmaceutical companies. We expect that productive research and development activity will yield effective disease treatments that improve the quality of patients’ lives, characteristics that historically have been the source of longer-term outperformance in the sector.

From Spiros Segalas (Trades, Portfolio)' Harbor Capital Appreciation Fund Managers' second quarter 2017 commentary.

Check out Spiros Segalas latest stock trades

Top Ranked Articles about Celgene Corp

Celgene Acquires Company Investigating Cancer Warfare Drug Juno Therapeutics stock jumped 27% after $9 billion deal was announced
One of the largest biopharmaceutical players in the world, Celgene Corp. (NASDAQ:CELG), has announced a $9 billion deal to acquire Juno Therapeutics Inc. (NASDAQ:JUNO) as part of its plans to ramp up development of experimental blood-cancer drugs. Read more...
3 Stocks Move in Premarket Trading Monday FirstEnergy and Juno Therapeutics up, Freeport-McMoRan down
In Monday premarket trading, FirstEnergy Corp. (NYSE:FE) gained more than 10% after the company announced a $2.5 billion investment, which includes $1.62 billion in mandatory convertible preferred equity and $850 million of common equity. Read more...
Fledgling Biotech Company's Stock Surges Iovance Biotherapeutics develops cancer immunotherapy treatments
Shares of fledgling biotech company Iovance Biotherapeutics Inc. (NASDAQ:IOVA) were up almost 12% in early afternoon trading as the company moves forward on some promising cancer immunotherapy treatments. Read more...
Juno's Stock High on Possible Acquisition Celgene in talks to buy Juno
U.S. stock markets are set to open high on Wednesday with the Dow above the 26,000 level and the corporate earnings season as the principal driver of the bull market. The industrial production rose 0.9% in December for the fourth straight monthly increase and was higher than Wall Street expectations. Leaving behind the drop of the past quarter, in the fourth quarter, production advanced at an 8.2% annual rate. For the calendar year, production rose 3.6%. Read more...
David Rolfe Comments on Celgene Guru stock highlight
4 Stocks Move to Start the Week Verizon, Celgene, Bluebird Bio rise, Cleantech Solutions falls
Shares of Verizon Communications Inc. (NYSE:VZ) traded higher on news of a $2.25 billion deal with the National Football League. The deal will expand live-streaming of games for all mobile devices, regardless of network. Read more...
Thinking about investing in bluebird bio Inc., Celgene, Gilead Sciences, SunPower or Waste Management?
Building a Circle of Competency My journey of building a circle of competency in the pharmaceutical business
In my previous article I shared my favorite quotes from Li Lu on the subject of circle of competency. While those quotes are great, they won’t have any practical value unless we can actually put them into practice. Today I’ll share my journey of building a circle of competency (could very well be a circle of incompetence) in the pharmaceutical business. Read more...
Analysis: Positioning to Benefit within Kirby, AmerisourceBergen, Celgene, Sabre, Noble Energy, and Idera Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results
Stanley Druckenmiller Starts 3 Positions in 3rd Quarter Guru reports quarterly portfolio
Stanley Druckenmiller (Trades, Portfolio), former partner of George Soros (Trades, Portfolio)’s Quantum Fund, initiated three positions during the third quarter: Citigroup Inc. (NYSE:C), Chubb Ltd. (NYSE:CB) and Celgene Corp. (NASDAQ:CELG). Read more...

Ratios

vs
industry
vs
history
PE Ratio 25.17
CELG's PE Ratio is ranked lower than
66% of the 247 Companies
in the Global Biotechnology industry.

( Industry Median: 29.02 vs. CELG: 25.17 )
Ranked among companies with meaningful PE Ratio only.
CELG' s PE Ratio Range Over the Past 10 Years
Min: 17.92  Med: 42.79 Max: 230.5
Current: 25.17
17.92
230.5
Forward PE Ratio 12.03
CELG's Forward PE Ratio is ranked higher than
68% of the 68 Companies
in the Global Biotechnology industry.

( Industry Median: 24.21 vs. CELG: 12.03 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 25.17
CELG's PE Ratio without NRI is ranked lower than
65% of the 245 Companies
in the Global Biotechnology industry.

( Industry Median: 29.70 vs. CELG: 25.17 )
Ranked among companies with meaningful PE Ratio without NRI only.
CELG' s PE Ratio without NRI Range Over the Past 10 Years
Min: 17.82  Med: 42.63 Max: 215.13
Current: 25.17
17.82
215.13
Price-to-Owner-Earnings 24.82
CELG's Price-to-Owner-Earnings is ranked lower than
53% of the 145 Companies
in the Global Biotechnology industry.

( Industry Median: 38.46 vs. CELG: 24.82 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
CELG' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 15.44  Med: 38.39 Max: 922
Current: 24.82
15.44
922
PB Ratio 8.49
CELG's PB Ratio is ranked lower than
87% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. CELG: 8.49 )
Ranked among companies with meaningful PB Ratio only.
CELG' s PB Ratio Range Over the Past 10 Years
Min: 4.02  Med: 9.09 Max: 18.15
Current: 8.49
4.02
18.15
PS Ratio 6.88
CELG's PS Ratio is ranked higher than
54% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. CELG: 6.88 )
Ranked among companies with meaningful PS Ratio only.
CELG' s PS Ratio Range Over the Past 10 Years
Min: 5.37  Med: 9.19 Max: 25.21
Current: 6.88
5.37
25.21
Price-to-Free-Cash-Flow 19.00
CELG's Price-to-Free-Cash-Flow is ranked higher than
57% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 36.07 vs. CELG: 19.00 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
CELG' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 14.87  Med: 31.38 Max: 336.15
Current: 19
14.87
336.15
Price-to-Operating-Cash-Flow 18.03
CELG's Price-to-Operating-Cash-Flow is ranked lower than
52% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 25.45 vs. CELG: 18.03 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CELG' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 13.85  Med: 28.74 Max: 187.62
Current: 18.03
13.85
187.62
EV-to-EBIT 20.75
CELG's EV-to-EBIT is ranked lower than
63% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. CELG: 20.75 )
Ranked among companies with meaningful EV-to-EBIT only.
CELG' s EV-to-EBIT Range Over the Past 10 Years
Min: -28.6  Med: 31.55 Max: 90.4
Current: 20.75
-28.6
90.4
EV-to-EBITDA 18.54
CELG's EV-to-EBITDA is ranked lower than
64% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. CELG: 18.54 )
Ranked among companies with meaningful EV-to-EBITDA only.
CELG' s EV-to-EBITDA Range Over the Past 10 Years
Min: -31.4  Med: 26.85 Max: 83
Current: 18.54
-31.4
83
EV-to-Revenue 6.90
CELG's EV-to-Revenue is ranked higher than
57% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. CELG: 6.90 )
Ranked among companies with meaningful EV-to-Revenue only.
CELG' s EV-to-Revenue Range Over the Past 10 Years
Min: 5.1  Med: 9.15 Max: 25.7
Current: 6.9
5.1
25.7
PEG Ratio 1.52
CELG's PEG Ratio is ranked lower than
62% of the 101 Companies
in the Global Biotechnology industry.

( Industry Median: 2.09 vs. CELG: 1.52 )
Ranked among companies with meaningful PEG Ratio only.
CELG' s PEG Ratio Range Over the Past 10 Years
Min: 1.25  Med: 2.32 Max: 3.26
Current: 1.52
1.25
3.26
Shiller PE Ratio 67.16
CELG's Shiller PE Ratio is ranked lower than
74% of the 70 Companies
in the Global Biotechnology industry.

( Industry Median: 41.36 vs. CELG: 67.16 )
Ranked among companies with meaningful Shiller PE Ratio only.
CELG' s Shiller PE Ratio Range Over the Past 10 Years
Min: 62.13  Med: 135.32 Max: 3211
Current: 67.16
62.13
3211
Current Ratio 3.65
CELG's Current Ratio is ranked lower than
51% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. CELG: 3.65 )
Ranked among companies with meaningful Current Ratio only.
CELG' s Current Ratio Range Over the Past 10 Years
Min: 1.35  Med: 7.15 Max: 44.53
Current: 3.65
1.35
44.53
Quick Ratio 3.52
CELG's Quick Ratio is ranked higher than
51% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. CELG: 3.52 )
Ranked among companies with meaningful Quick Ratio only.
CELG' s Quick Ratio Range Over the Past 10 Years
Min: 1.13  Med: 7.02 Max: 44.15
Current: 3.52
1.13
44.15
Days Inventory 414.70
CELG's Days Inventory is ranked lower than
91% of the 473 Companies
in the Global Biotechnology industry.

( Industry Median: 134.39 vs. CELG: 414.70 )
Ranked among companies with meaningful Days Inventory only.
CELG' s Days Inventory Range Over the Past 10 Years
Min: 104.34  Med: 244.42 Max: 414.7
Current: 414.7
104.34
414.7
Days Sales Outstanding 53.05
CELG's Days Sales Outstanding is ranked higher than
62% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. CELG: 53.05 )
Ranked among companies with meaningful Days Sales Outstanding only.
CELG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 43.42  Med: 57.78 Max: 71.27
Current: 53.05
43.42
71.27
Days Payable 210.98
CELG's Days Payable is ranked higher than
86% of the 434 Companies
in the Global Biotechnology industry.

( Industry Median: 57.10 vs. CELG: 210.98 )
Ranked among companies with meaningful Days Payable only.
CELG' s Days Payable Range Over the Past 10 Years
Min: 61.81  Med: 139.99 Max: 210.98
Current: 210.98
61.81
210.98

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 1.70
CELG's 3-Year Average Share Buyback Ratio is ranked higher than
98% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. CELG: 1.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CELG' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -25.1  Med: -5.3 Max: 4.5
Current: 1.7
-25.1
4.5

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.79
CELG's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
60% of the 171 Companies
in the Global Biotechnology industry.

( Industry Median: 3.43 vs. CELG: 1.79 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
CELG' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.66  Med: 4.88 Max: 124
Current: 1.79
1.66
124
Price-to-Median-PS-Value 0.75
CELG's Price-to-Median-PS-Value is ranked lower than
54% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. CELG: 0.75 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CELG' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.61  Med: 2.07 Max: 30
Current: 0.75
0.61
30
Price-to-Peter-Lynch-Fair-Value 1.35
CELG's Price-to-Peter-Lynch-Fair-Value is ranked lower than
69% of the 65 Companies
in the Global Biotechnology industry.

( Industry Median: 1.79 vs. CELG: 1.35 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
CELG' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.36  Med: 1.81 Max: 5.1
Current: 1.35
0.36
5.1
Earnings Yield (Greenblatt) % 4.81
CELG's Earnings Yield (Greenblatt) % is ranked higher than
84% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. CELG: 4.81 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CELG' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -7.5  Med: 2.9 Max: 6.7
Current: 4.81
-7.5
6.7
Forward Rate of Return (Yacktman) % 22.00
CELG's Forward Rate of Return (Yacktman) % is ranked higher than
60% of the 132 Companies
in the Global Biotechnology industry.

( Industry Median: 13.13 vs. CELG: 22.00 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
CELG' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 0.1  Med: 2.4 Max: 34.8
Current: 22
0.1
34.8

More Statistics

Revenue (TTM) (Mil) $12,495.20
EPS (TTM) $ 4.22
Beta1.21
Short Percentage of Float1.75%
52-Week Range $94.55 - 147.17
Shares Outstanding (Mil)787.32

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 12,961 14,829 17,580 20,460
EPS ($) 6.96 8.25 9.94 11.84
EPS without NRI ($) 6.96 8.25 9.94 11.84
EPS Growth Rate
(Future 3Y To 5Y Estimate)
21.44%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 88
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}